Gene Repair Technology Restores Dystrophin Expression in Canine Model of Duchenne
We are encouraged to learn that Exonics Therapeutics, Inc., a biotechnology company focused on developing gene editing therapies to treat patients with Duchenne and other neuromuscular diseases, today announced the publication of a preclinical study…Learn More
